Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Meaningful Dilution CLDX is well-capitalized with low leverage, but severe losses, cash burn, dilution, and a premium 4.57x book valuation make it a high-risk, development-stage investment.
Price Behavior
Key Price Behavior Insights: ⢠Sharp downtrend ⢠Oversold momentum ⢠Resistance overhead Support Level: $36.90 (unconfirmed) Resistance Level: $39.10â$39.70 CLDX is in a bearish last-month downtrend, but oversold momentum may support a short-term rebound if it reclaims $39.10â$39.70; a break below $36.90 would signal further weakness.
Sentiment & News
Key News Insights: ⢠Fiduciary-duty inquiry ⢠Investor conference ⢠Mixed sentiment Celldex faces shareholder-related legal scrutiny while maintaining investor outreach through an upcoming healthcare conference appearance.
AI Summary
CLDX is now a concentrated, catalyst-driven bet on Phase 3 barzolvolimab in CSU: durable efficacy could create a differentiated franchise, but the prurigo nodularis failure highlights that expansion value is uncertain and a pivotal miss would be disproportionately damaging. Investors should prioritize upcoming CSU validation against ongoing cash burn and dilution rather than treating the oversold share price as a fundamental entry signal.
Description
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibody therapies for inflammatory conditions and various cancers. Its clinical pipeline includes programs directed at KIT, CD40 and a bispecific combining PD-L1 blockade with CD27 costimulation, among other antibody candidates. The company maintains research and licensing relationships with academic institutions and Amgen, and is headquartered in Hampton, New Jersey, having been incorporated in 1983.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | CLDX | Celldex Therapeutics, Inc. | Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade. | Closed | -4.2% |